A consecutive series of 118 total hip arthroplasties was performed for Crowe type IV developmental hip dysplasia in 89 patients. The mean age of the patients was 52 years. All procedures were carried out through a transtrochanteric approach by the same surgeon. In all cases, the acetabular component was placed at the level of the true acetabulum. The mean lengthening of the operated limb was 3.8 cm. The average follow-up of the whole series was 12.8 years. At the last follow-up evaluation, 29 patients (35 hips) had died or were lost to follow-up at a mean of 11 years. Sixty patients (83 hips) were still alive at a mean follow-up of 16 years. At the time of last follow-up, the mean Merle d'Aubigné hip score was 17.4 compared with 10.6 preoperatively. The survival rate, with revision for any reason as the endpoint, was 78% at 20-year follow-up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1054/arth.2001.28368 | DOI Listing |
Am J Sports Med
January 2025
Section of Young Adult Hip Surgery, Division of Sports Medicine, Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.
Background: Many studies have examined the prevalence of acetabular version (AV) and femoral version (FV) abnormalities and their effect on patient-reported outcomes (PROs) after hip arthroscopy for femoroacetabular impingement syndrome (FAIS), but few have explored the prevalence and influence of combined version (CV) abnormalities.
Purpose: To (1) describe the distribution of AV, FV, and CV in the largest cohort to date and (2) determine the relationship between AV, FV, and CV and PROs after hip arthroscopy for FAIS.
Study Design: Cohort study; Level of evidence, 3.
Arthroscopy
January 2025
American Hip Institute Research Foundation, Chicago, IL 60018; American Hip Institute, Chicago, IL 60018. Electronic address:
Purpose: To identify the PASS and SCB thresholds for hip arthroscopy and provide guidance on how to choose among the thresholds.
Methods: A systematic review of literature was conducted in PubMed and MEDLINE databases in August 2024 using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Studies with Level I to IV evidence that defined SCB or PASS thresholds for PROs for hip arthroscopy in the setting of intra-articular pathology were included.
Arthroscopy
January 2025
American Hip Institute Research Foundation, Chicago, IL 60018. Electronic address:
Purpose: To identify sex-based differences in pathology, outcomes, and complications after hip arthroscopy for femoroacetabular impingement (FAI), and to compare patient-reported outcomes (PRO) scores between males and females.
Methods: The PubMed and MEDLINE databases were searched in September 2024, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Included studies had data stratified by sex, minimum 2-year patient reported outcome (PRO) scores for hip arthroscopy in the setting of FAI and labral pathology, and a 2014 or later publication date.
Background: Postoperative cognitive dysfunction (POCD) is a postoperative complication of the central nervous system, especially in elderly patients. Growing evidence shows a close relationship between the kidney and cognition. This study aimed to evaluate the relationship between the subsequent risk of POCD and indicators related to the kidney.
View Article and Find Full Text PDFBMC Musculoskelet Disord
January 2025
Department of Orthopedics and Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Background: Osteonecrosis of the femoral head (ONFH) is a challenging condition, primarily affecting young and middle-aged individuals, which results in hip dysfunction and, ultimately, femoral head collapse. However, the comparative effectiveness of joint-preserving procedures, particularly in the early stages of ONFH (ARCO stage I or II), remains inconclusive. This study aims to evaluate the efficacy of a novel technique called small-diameter core decompression (CD) combined with platelet-rich plasma (PRP), for the treatment of early-stage ONFH.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!